Statistics

Total Visits

Views
Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab51

Select a period of time:

Number of views in the range

Views
Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab32

Views

Views
January 20252
February 20255
March 202517
April 20254
May 20253
June 20251
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United States14
Germany1
Spain1
France1
 

Top cities views

Views
Council Bluffs1